<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02392702</url>
  </required_header>
  <id_info>
    <org_study_id>CP656.1001</org_study_id>
    <nct_id>NCT02392702</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Safety, Tolerability and PK of C-10355 and C-10358 in Healthy Subjects</brief_title>
  <official_title>A Two-Part Open-Label, Randomized, Sequential, Crossover, Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of C-10355 and C-10358 in Healthy Volunteers, With a PK Comparison to Kalydeco®</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Concert Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Concert Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This two-part study will assess, in healthy volunteers, under both fasted and fed conditions,
      and in a sequential manner, the safety, tolerability and pharmacokinetics (PK) profile of
      single doses of C-10355 and C-10358 and single ascending doses of the selected compound
      compared to a single dose of Kalydeco®.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>24 hours</time_frame>
    <description>adverse events categorized by body system and MedDRA term</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Profile</measure>
    <time_frame>96 hours</time_frame>
    <description>Measure exposure of test articles using area under the concentration time curve (AUC), maximum concentration (Cmax), half life (T 1/2)</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>C-10355, 25 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single oral dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C-10358, 25 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single oral dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C-10355 or C-10358, 75 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single oral dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C-10355 or C-10358, 150 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single oral dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Kalydeco, 150 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single oral dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C-10355 or C-10358, 300 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single oral dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C-10355</intervention_name>
    <arm_group_label>C-10355, 25 mg</arm_group_label>
    <arm_group_label>C-10355 or C-10358, 75 mg</arm_group_label>
    <arm_group_label>C-10355 or C-10358, 150 mg</arm_group_label>
    <arm_group_label>C-10355 or C-10358, 300 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C-10358</intervention_name>
    <arm_group_label>C-10358, 25 mg</arm_group_label>
    <arm_group_label>C-10355 or C-10358, 75 mg</arm_group_label>
    <arm_group_label>C-10355 or C-10358, 150 mg</arm_group_label>
    <arm_group_label>C-10355 or C-10358, 300 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kalydeco</intervention_name>
    <arm_group_label>Kalydeco, 150 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adults between 18 and 50 years of age, inclusive

          -  Body weight ≥ 50 kg and BMI within the range of 18 to 30 kg/m2, inclusive, at
             screening

        Exclusion Criteria:

          -  History of clinically significant central nervous system (eg, seizures), cardiac,
             pulmonary, metabolic, renal (including nephrolithiasis), hepatic, including history of
             Gilbert's syndrome or gastrointestinal (GI) conditions

          -  PR interval ≥ 220 msec or QRS duration ≥ 120 msec or QTcF interval &gt; 450 msec obtained
             at screening visit or prior to the first dose of study drug

          -  Liver function tests greater than the upper limit of normal.

          -  Positive blood screen for human immunodeficiency virus (HIV antibody), hepatitis B
             virus surface antigen, or hepatitis C virus antibody at screening

          -  Urinalysis positive for greater than trace blood, protein or glucose

          -  A positive screen for alcohol, drugs of abuse, or tobacco use.

          -  Inability to comply with food and beverage restrictions during study participation.

          -  Donation or blood collection or acute loss of blood prior to screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lana Pilja</last_name>
    <role>Study Director</role>
    <affiliation>Concert Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CMAX</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2015</study_first_submitted>
  <study_first_submitted_qc>March 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2015</study_first_posted>
  <last_update_submitted>September 22, 2015</last_update_submitted>
  <last_update_submitted_qc>September 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Subjects</keyword>
  <keyword>Safety/Efficacy Study</keyword>
  <keyword>Randomized</keyword>
  <keyword>Open Label</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivacaftor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

